Humans: a single group. Cells, worms or flies and mice: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Includes the processes named after it and trials of drugs aimed at it.
4 independent labs in 2 countries
9 trials, 1 with no results posted
Funders: National Natural Science Foundation of China and others
9 of 9 trials sponsored by developers of drugs aimed at it
Human trial6
Humans11
Animals1
Cells1
Effects
3
LIPG
↓downin humans1
1 study
ANGPTL3 inhibits LIPG in humans.
“ANGPTL3 influences triglycerides, LDL-C, and high-density lipoprotein cholesterol through inhibition of lipoprotein lipase and endothelial lipase.”
“ANGPTLs-particularly the triad ANGPTL3, 4, and 8-have an established role in lipid metabolism through the regulation of triacylglycerol trafficking according to the nutritional status.”
Risk of coronary artery disease, peripheral artery disease, and aortic stenosis
↔no changein humans1
1 study
ANGPTL3 is associated with risk of coronary artery disease, peripheral artery disease, and aortic stenosis in humans (Genetically proxied ANGPTL3 inhibition) (Minimal association).
“genetically-proxied ANGPTL3 inhibition had minimal association with CAD, PAD, AS and a modest association with lower AAA risk.”
ANGPTL3 is linked with a lower risk of chronic kidney disease in humans (genetically proxied inhibition; per 1-SD decrease in triglycerides) (OR 0.76 [95% CI 0.69 to 0.84]).
“genetically proxied ANGPTL3 inhibition, ANGPTL4 inhibition, and lipoprotein lipase enhancement were associated with lower CKD risk”
Humansgenetically proxied inhibition; per 1-SD decrease in triglycerides
ANGPTL3 is linked with a higher risk of renal cell carcinoma in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 1.975 (95% CI 1.217-3.205)).
“ANGPTL3 inhibition was also associated with an increased risk of renal cell carcinoma (OR =1.975; 95% CI: 1.217-3.205)”
ANGPTL3 is linked with a higher risk of prostate cancer in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 1.365 (95% CI 1.091-1.709)).
“Genetically proxied inhibition of ANGPTL3 was associated with a higher risk of prostate cancer [odds ratio (OR) =1.365; 95% confidence interval (CI): 1.091-1.709]”
Human genetic analyses linked lower activity of one fat-regulating protein to lower risks of four cardiovascular diseases, while a related protein showed little…Human genetic analyses linked lower activity of one fat-regulating protein to lower risks of four cardiovascular diseases, while a related protein showed little association with three.
Who was studiedParticipants in human genetic studies
What changedGenetically predicted ANGPTL4 inhibition was linked to lower cardiovascular risks; ANGPTL3 inhibition had little association with most outcomes
The catchGenetic stand-ins do not measure effects of drugs targeting these proteins